Paul Myners, commissioned by the government to review rules on pre-emption rights, has recommended that the UK's biotechnology sector be made a special case when raising funds through new share issues.

The government commissioned his report to assess whether these rights, which give existing shareholders first refusal when a company issues new shares, are an obstacle to research and development-based companies raising funds to innovate